Krishnan Viswanadhan - 01 Mar 2026 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Signature
/s/ William Cook, as Attorney in Fact for Krishnan Viswanadhan
Issuer symbol
AGIO
Transactions as of
01 Mar 2026
Net transactions value
$0
Form type
4
Filing time
03 Mar 2026, 16:11:25 UTC
Previous filing
19 Aug 2025
Next filing
09 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Viswanadhan Krishnan Chief Corp Dev & Strategy 88 SIDNEY STREET, CAMBRIDGE /s/ William Cook, as Attorney in Fact for Krishnan Viswanadhan 03 Mar 2026 0001999913

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Restricted stock units Award $0 +14,000 $0.000000 14,000 01 Mar 2026 Common stock 14,000 Direct F1, F2
transaction AGIO Stock options (right to buy) Award $0 +52,000 $0.000000 52,000 01 Mar 2026 Common stock 52,000 $30.23 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2 The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.
F3 This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.